BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 01, 2009
 |  BioCentury  |  Finance

Cytokinetics chronicles

Cytokinetics chronicles

Cytokinetics Inc. (NASDAQ:CYTK) was up 31% to $2.72 last week after Amgen Inc. (NASDAQ:AMGN) exercised its option to license exclusive, worldwide rights, ex-Japan, to Cytokinetics' cardiac contractility program, including CK-1827452. The cardiac myosin activator is in Phase II testing to treat heart failure. Cytokinetics will receive $50 million up front and is eligible for up to $600 million in milestones, plus double-digit royalties. Cytokinetics shares have fallen 83% since its IPO in April 2004,...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >